Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse
- PMID: 7937814
- PMCID: PMC44862
- DOI: 10.1073/pnas.91.20.9607
Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse
Abstract
Atherosclerosis is a complex disease with both genetic and environmental determinants. Apolipoprotein (Apo) E-deficient mice have been created that are highly susceptible to atherosclerosis. In order to assess the role of human apolipoprotein (hApo) A-I and high density lipoprotein (HDL) in atherosclerosis susceptibility, transgenic mice overexpressing the hApo A-I gene were crossed with Apo E-deficient mice. Apo E-/-, hApo A-I mice with two-fold elevation in HDL cholesterol have markedly diminished atherosclerosis with less fibroproliferative lesions by 8 months of age. A strong reciprocal relationship between HDL cholesterol levels and atherosclerosis was found with HDL levels accounting for 78% of the observed variance in mean lesion area. The effect of HDL on atherosclerosis resistance was independent of non-HDL cholesterol.
Similar articles
-
The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice.Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):407-12. doi: 10.1073/pnas.012587699. Epub 2001 Dec 18. Proc Natl Acad Sci U S A. 2002. PMID: 11752403 Free PMC article.
-
Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice.J Lipid Res. 1994 Dec;35(12):2263-7. J Lipid Res. 1994. PMID: 7897323
-
Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice.J Clin Invest. 1994 Aug;94(2):899-903. doi: 10.1172/JCI117412. J Clin Invest. 1994. PMID: 8040345 Free PMC article.
-
Gene activation, apolipoprotein A-I/high density lipoprotein, atherosclerosis prevention and longevity.Pharmacol Toxicol. 1997 Aug;81(2):57-64. doi: 10.1111/j.1600-0773.1997.tb00032.x. Pharmacol Toxicol. 1997. PMID: 9298501 Review.
-
Mouse models of atherosclerosis.Curr Opin Lipidol. 2001 Apr;12(2):167-73. doi: 10.1097/00041433-200104000-00010. Curr Opin Lipidol. 2001. PMID: 11264988 Review.
Cited by
-
Oxidative modification of HDL by lipid aldehydes impacts HDL function.Arch Biochem Biophys. 2022 Nov 15;730:109397. doi: 10.1016/j.abb.2022.109397. Epub 2022 Sep 15. Arch Biochem Biophys. 2022. PMID: 36116503 Free PMC article. Review.
-
Novel Therapy for Atherosclerosis Using Recombinant Immunotoxin Against Folate Receptor β-Expressing Macrophages.J Am Heart Assoc. 2012 Aug;1(4):e003079. doi: 10.1161/JAHA.112.003079. Epub 2012 Aug 24. J Am Heart Assoc. 2012. PMID: 23130174 Free PMC article.
-
HDL, Atherosclerosis, and Emerging Therapies.Cholesterol. 2013;2013:891403. doi: 10.1155/2013/891403. Epub 2013 May 28. Cholesterol. 2013. PMID: 23781332 Free PMC article.
-
Gene therapy for dyslipidemia: clinical prospects.Curr Atheroscler Rep. 1999 Jul;1(1):58-69. doi: 10.1007/s11883-999-0051-5. Curr Atheroscler Rep. 1999. PMID: 11122693 Review.
-
Biochemical characterization of cholesteryl ester transfer protein inhibitors.J Lipid Res. 2010 Sep;51(9):2739-52. doi: 10.1194/jlr.M007468. Epub 2010 May 10. J Lipid Res. 2010. PMID: 20458119 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases